Measles infection induces lifelong immunity; however, wild-type infection stimulates higher levels of measles-virus-neutralizing antibodies (mnAbs) than does vaccination. Because the proportion of the donor population with vaccine-induced measles immunity is increasing, this study was conducted to determine whether this shift in demographic characteristics affects mnAb levels in contemporary lots of Immune Globulin Intravenous (Human) (IGIV). When 166 lots of 7 IGIV products manufactured between 1998 and 2003 were assayed by plaque-reduction neutralization test, there was a progressive decrease in geometric mean titers in lots manufactured between 1999 and 2002. IGIV products manufactured from recovered plasma had significantly higher titers than did those manufactured from Source Plasma, which could reflect a change in donor demographic characteristics, because Source Plasma donors tend to be much younger. A reduction in mnAbs also correlated with the loss of either IgG1 and IgG3, possibly because of certain manufacturing procedures, or bivalent antibodies (i.e., intact IgG and F(ab')2), because of fragmentation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1086/506363 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapid quantitative detection system for measles virus-neutralizing antibodies using HiBiT-tagged virus-like particles.
Microbiol Immunol
April 2024
Department of Virology 3, National Institute of Infectious Diseases, Tokyo, Japan.
Immunological testing to detect neutralizing antibodies (NAbs) is important in measles (MV) infection control. Currently, the plaque reduction neutralization test is the only credible method for measuring actual virus NAbs; however, its feasibility is hampered by drawbacks, such as long turnaround times, low throughput, and the need for laboratory biosafety equipment. To solve these problems, we developed a simple and rapid MV-NAb detection system using lentivirus-based virus-like particles incorporated with the NanoLuc fragment peptide HiBiT comprising the MV fusion protein and hemagglutinin on their exterior surface.
View Article and Find Full Text PDFMeasles Virus Neutralizing Antibody Response and Durability Two Years after One or Two Doses of Measles-Mumps-Rubella Vaccine among Young Seronegative Healthcare Workers.
Vaccines (Basel)
October 2022
Department of Internal Medicine, Division of Infectious Diseases, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14100, Korea.
Article Synopsis
- There is limited research on how long the immune response from MMR vaccine booster doses lasts compared to natural measles infection, particularly in young adults.
- The study involved seronegative healthcare workers who received the MMR vaccine and those with confirmed measles during a 2019 outbreak, analyzing their antibody levels two years later.
- Results indicated that those who had natural measles infection showed significantly higher antibody levels than those vaccinated, implying a need for monitoring immune responses in healthcare workers during measles outbreaks.
Qualitative Variation among Commercial Immunoassays for Detection of Measles-Specific IgG.
J Clin Microbiol
May 2020
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Article Synopsis
- The study evaluates the reliability of five commercially available tests for measuring measles virus-specific IgG antibodies to determine immunity in individuals with uncertain vaccination status.
- False-negative results can lead to unnecessary quarantine or revaccination, while false-positive results may allow susceptible individuals to inadvertently spread the disease.
- Discrepancies were found mainly in low-positive samples, but overall, the tests performed well for confirming negative IgG status and intermediate to high levels of IgG, with about 11% of low-antibody sera yielding false negatives.
Measles virus neutralizing antibodies in immunoglobulin lots produced from plasma collected in Europe or the United States.
Vaccine
May 2019
Global Pathogen Safety, Baxter AG, 1221 Vienna, Austria(1). Electronic address:
Vaccination against measles has reduced disease, although measles virus antibody (MVAb) levels are lower after vaccination than natural infection. Immunoglobulin (IG) preparations thus contain decreasing MVAb titers. US IG lot release requires a minimum titer of MVAb, yet equivalent information is not available for other geographies.
View Article and Find Full Text PDFCorrelation between the results of two analytical methods for measuring measles virus neutralizing antibodies in source plasma and therapeutic immunoglobulin products.
Biologicals
May 2019
Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, 02841, Anam-dong, Seoungbuk-gu, Seoul, Republic of Korea. Electronic address:
Patients with primary immunodeficiency disorders are vulnerable to infectious diseases. Intravenous immunoglobulin (IVIG) therapeutic products manufactured from human plasma are employed widely to protect patients from pathogens such as measles virus, which causes a potentially fatal and contagious disease. Therefore, health authorities stipulate a minimum titer of measles neutralizing antibodies (mnAbs) in IVIG products to ensure efficient protection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!